期刊文献+

恶性疟原虫裂殖子表面蛋白3功能区片段的制备及其免疫原性分析 被引量:1

The Production and Immunogenicity of the Functional Fragment of Plasmodium falciparum Merozoite Surface Protein 3
下载PDF
导出
摘要 目的构建恶性疟原虫裂殖子表面蛋白3功能片段MSP3(69)与谷胱甘肽(GST)的融合蛋白,并在大肠杆菌中进行表达,分析其免疫原性。方法采用大肠杆菌系统表达融合蛋白GST-MSP3(69),以疟疾病人血清进行Western-blot,并以ISA720、佛氏、氢氧化铝与CpG联合3种佐剂与GST-MSP3(69)融合蛋白乳化,免疫Balb/ca小鼠,分析其免疫原性。结果在大肠杆菌系统中成功表达GST-MSP3(69)融合蛋白,疟疾病人血清能与融合蛋白反应。3种佐剂免疫Balb/ca小鼠均能诱发Balb/ca小鼠产生较高水平的特异抗体,3次免疫后的抗体滴度分别为4.5×105,4.1×105和3.5×105。3次免疫后血清抗体亚型分析显示该蛋白能够诱导Balb/ca小鼠产生较高滴度的亲细胞亚型IgG1和IgG2b,ISA720、佛氏、氢氧化铝与CpG联合佐剂组IgG1分别为8×104、7.8×104、6.8×104,IgG2b分别为1.2×104,1.25×104、1.5×104。统计学分析显示不同佐剂组的抗体滴度及抗体亚型滴度之间差异均无统计学意义(P>0.05)。结论制备了在大肠杆菌表达的GST-MSP3(69)融合蛋白,该蛋白具有高免疫原性,并产生亲细胞亚型抗体,这些为研究MSP3蛋白功能区的免疫保护作用打下了基础。 Objective To produce the functional fragment (184-252) of Merozoite Surface Protein 3 (MSP3) of Plasmodiumfalciparum and assess its immunogenicity in Balb/c mice. Method The functional fragment (184-252) of Merozoite Surface Protein 3 (MSP3) of Plasrnodiumfalciparum was fused with GST and the resulting fusion protein, designated GST-MSP3 (69), was expressed in E.coli. The recombinant GST-MSP3 (69) protein was detected with the sera by Western-blot. Balb/ca mice were immunized with the protein formulated by three adjuvants ISA720, Freund's and Alum combined with CPG1826. Result The recombinant fusion protein was recognized by the sera from the malaria patients. The antigen formulated with all of the three adujvants were highly immunogenic in mice with 4.5×10^5 in ISA 720, 4.1×10^5 in the Freund and 3.5×10^5 in the alum combined with CPG1826. Analysis of antibody isotypes showed that the predominant antibody were eytophilous IgG1 and IgG2b. The titer of IgG1 was 8×10^4,7.8×10^4 and 6.8×10^4 in ISA720, the Freund and the Alum combined with CPG1826, respectively, while the IgG2b was 1.2×10^4,1.25×10^4 and 1.5×10^4, in the three adjuvants, respectively. There was no statistically significant difference in the ELISA titer of the adjuvant. Conclusion The GST-MSP3(69) protein was successfully expressed in E.coli and the protein formulated with the three adjuvants were highly immunogenic with predominant IgG isotypes of IgG1 and IgG2b in mice.
出处 《热带医学杂志》 CAS 2008年第12期1199-1202,共4页 Journal of Tropical Medicine
基金 国家自然科学基金(No.30430610)
关键词 疟疾疫苗 GST-MSP3(69) 重组蛋白 免疫原性 malaria vaccine GST-MSP3(69) recombinant protein immunogenicity
  • 相关文献

参考文献12

  • 1Holder AA, Guevara Patino JA, Uthaipibull C, et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria [J]. Parassitol, 1999,41 (1-3) :409-414.
  • 2Weiqing Pan, Daqing Huang, Qingfeng Zhang, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro [J]. J Immunol, 2004,172(10): 6167-6174.
  • 3Nebie I, Diarra A, Ouedraogo A, et al. Humoral response to Plasmodium folciparum blood stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Mrica [ J ]. Infect Immun, 2008,76 (2) : 759-766.
  • 4Genton B, Betuela I, Felger I, et al. A recombinant blood- stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea [J]. J Infect Dis, 2002,185 (6) : 820-827.
  • 5Audran R, Cachat M, Spertini F, et al. Phase I malaria vaccine trail with a long synthetic peptide derived from the merozoite surface protein 3 antigen [J]. Infect Immun, 2005, 73(12) : 8017-8026.
  • 6Sirima Sodiomon B, Nebie I, Ouedraogo A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa [J]. Vaccine, 2007,25(14):2723-2732.
  • 7Polley Spencer D, Tetteh Kevin KA, Lloyd Jennie M, et al. Plasmodium folciparum merozoite surface protein 3 is a target of Allele-specific immunity and Alleles are maintained by natural selection [J]. J Infect Dis, 2007,195(2):279-287.
  • 8Bouharoun-Tayoun H, Noun G, Druilhe P, et al. Plasmodium falciparum: production of human antibodies specific for the MSP-3 protein in the Hu-SPL-SCID mouse [J]. Exp Parasitol, 2004, 108(1-2) :47-52.
  • 9Oeuvray C, Bouharoun-Tayoun Merozoite surface rotein-3: H, Gras-Masse H, et al. A malaria protein inducing antibodies that promote Hasmodium falciparum killing by cooperation with blood monocytes [J]. Blood, 1994,84(5): 1594-1602.
  • 10Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of MSP3 targeted by biologically active antibodies to improve vaccine design [J]. J Infect Dis, 2004,190(5): 1010-1018.

二级参考文献25

  • 1[1]Singh M, O'Hagan D.Advances in vaccine adjuvants [J]. Nat Biotechnol,1999,17(11):1075-1081.
  • 2[2]Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action[J].Vaccine,1997,15(3):248-256.
  • 3[3]Audibert MF, Lise LD. Adjuvants: current status, clinical perspectives and future prospects[J].Immunol Today,1993,14(6):281-284.
  • 4[4]Wagland BM, McClure SJ, Cossey SG, et al. Effect of Freund's adjuvants on guinea pigs infected with, or vaccinated against, Trichostrongylus colubriformis[J].Int J Parasitol,1996,26(1):85-90.
  • 5[5]Briand EJ, Ruble GR, Stiteler J, et al. Comparison of adjuvants with Leishmania antigens in a guinea pig model to induce delayed-type hypersensitivity responses[J].Lab Anim Sci,1999,49(5):519-521.
  • 6[6]Aucouturier J, Deville S, Perret C,et al. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis[J].Parasite,2001,8(2 Suppl):S126-132.
  • 7[7]Lawrence G, Saul A,Giddy AJ,et al. Phase I trial in humans of an oil-based adjuvant seppic montanide ISA 720[J].Vaccine,1997,15(2):176-178.
  • 8[8]Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant[J].Vaccine,1999,17(23-24):3145-3159.
  • 9[9]Gupta RK. Aluminum compounds as vaccine adjuvants[J]. Adv Drug Deliv Rev,1998,32(3):155-172.
  • 10[10]Matsumoto S, Yukitake H, Kanbara H, et al. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1[J].Vaccine,1999,18(9-10):832-834.

同被引文献24

  • 1张瑾,辛晓芳.疟疾疫苗研究进展[J].国外医学(预防.诊断.治疗用生物制品分册),2005,28(1):27-29. 被引量:1
  • 2周华,孙立新,朱昌亮.疟疾疫苗研究的主要进展[J].国外医学(寄生虫病分册),2005,32(2):72-76. 被引量:1
  • 3张忠广,赵恒梅,宫玉香.恶性疟原虫主要裂殖子表面蛋白1C末端片段在毕赤酵母表达系统的高效表达与纯化(英文)[J].中国人兽共患病杂志,2005,21(12):1047-1051. 被引量:3
  • 4王瑞,钱锋,曲莉,潘卫庆.恶性疟原虫融合抗原PfCP-2.9的单克隆抗体制备及功能分析[J].中国寄生虫学与寄生虫病杂志,2006,24(4):247-250. 被引量:1
  • 5WHO. World Malaria Report 2009[EB/OL]. http://www. who. int/malaria/world_malaria_report 2009/en/index. html.
  • 6Glyde DF. Immunity to falctparum and vivax malaria induced by trradiated review of the university of Maryland studies, 1971 - 1975[M]. Bull WHO, 1990.9- 12.
  • 7Ballou WR, Cahill CP. Two decades of commitment to malaria vaccine development : glaxosmithkline biologicals [J]. The American Society of Tropical Medicine and Hygiene, 2007,77(6) : 289- 95.
  • 8Grtchen V. A complex mew vaccine shows promise[J]. Science, 2004,306..587-9.
  • 9Jose AS, Gray D, Heppner JR. Phase 1 Safety and immunogenicity trial of malaria vaccine RTS,S/ASo2A in adults in a hyperendemic region of Western Kenya[J]. Am J Trop Med Hyg, 2006,75 (1):166-70.
  • 10Cevayir C,Ken JI,Anthony WS.Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25,a Plasmodium falciparum transmission-blocking vaccine antigen[J].Infect Immu,2004,1:584-8.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部